阿斯利康英飞凡在华获批

Core Viewpoint - AstraZeneca announced that its drug Imfinzi (generic name: Durvalumab) has been approved by the National Medical Products Administration (NMPA) in China for use as a monotherapy in adult patients with limited-stage small cell lung cancer (LS-SCLC) who have not experienced disease progression after platinum-based chemoradiotherapy [1] Group 1 - The approval of Imfinzi marks a significant advancement in the treatment options available for LS-SCLC patients in China [1] - The drug is specifically indicated for patients who have undergone platinum-based chemoradiotherapy without disease progression [1]